Clinical Trials Sponsored by CellMed AG, a subsidiary of BTG plc

Total 4 results

CellMed AG, a subsidiary of BTG plc.

Completed

Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes

Type II Diabetes Mellitus

Germany
CellMed AG, a subsidiary of BTG plc.

Terminated

GLP-1 CellBeads® for the Treatment of Stroke Patients With Space-occupying Intracerebral Hemorrhage

Intracerebral Hemorrhage (ICH)

Germany
CellMed AG, a subsidiary of BTG plc.

Completed

Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Multiple Ascending Doses of CM3.1-AC100 in Healthy Male Volunteers

Healthy

Germany
CellMed AG, a subsidiary of BTG plc.

Completed

First in Man Clinical Study to Investigate Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of CM3.1-AC100

Healthy

Germany

3

Subscribe